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Group A streptococci contain certain antigens that are immunologically cross- 
reactive with human tissues, especially the myocardium (1-8). Some of the cross- 
reactive antigens have been identified as components of the protoplast membrane 
(3,  8),  while others have been  localized to the cell wall (2,  5,  6).  The precise 
location of these host tissue-cross-reactive antigens within the streptococcus is of 
considerable interest to investigators attempting to develop vaccines composed 
of purified M proteins, the protective surface antigens of group A streptococci. 
Because  M  protein  vaccines  are  intended  to  protect  the  host  against  acute 
rheumatic fever, a nonsuppurative sequela of streptococcal pharyngitis, the fear 
has been  that host tissue-cross-reactive  antigens contained within  the vaccine 
may theoretically cause, rather than prevent, the disease. 
Indeed, recent studies in our laboratory (9) have shown that type 5 M protein 
contains within its covalent structure at least one heart cross-reactive epitope. 
The purified heart-cross-reactive antibodies opsonized types 5 and  19 strepto- 
cocci, indicating that they were directed against protective M protein epitopes. 
These  results  indicate  the  need  to  precisely  identify  the  heart-cross-reactive 
antigenic determinants on  M  protein  molecules of potentially rheumatogenic 
serotypes of group A  streptococci so that these regions may be excluded from 
vaccine preparations. 
In  the present  study,  we  show  that  highly purified  M  proteins from three 
different serotypes of rheumatogenic streptococci contain antigens that cross- 
react with sarcolemmal membrane proteins of human myocardium. The number 
and distribution of these epitopes on each purified M protein were determined 
by  using  a  combination  of immunofluorescence inhibition  tests  and  enzyme- 
linked  immunosorbent assays.  The  affinity-purified,  heart-reactive  antibodies 
opsonized all three serotypes of streptococci, indicating that they were directed 
against protective M protein epitopes that were exposed on the surface of virulent 
organisms. Immunoblot analyses were used to identify the human sarcolemmal 
membrane proteins containing the cross-reactive antigens and to demonstrate 
their M protein serotype specificity. 
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Materials and  Methods 
Extraction and Purification of M  Proteins.  M proteins were purified from limited peptic 
extracts of types 5, 6,  19, and 24 group A streptococci (10-13). The purified M proteins 
(pep M) ~ were judged to be homogeneous by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) (10). 
Immunization  of Animals.  Three New Zealand White rabbits were immunized with a 
single  injection  of 300  ug  of pep  M5  emulsified  in  complete Freund's  adjuvant  (10). 
Serum was obtained before the first injection and at 2-wk intervals thereafter. Only the 
immune sera from those rabbits whose preimmune serum did not contain heart-reactive 
antibodies (see below) were used in these studies. 
M Protein Antibody Assays.  Rabbit antisera were tested for the presence of type-specific 
and  cross-reactive  M  protein  antibodies  by  an  enzyme-linked  immunosorbent  assay 
(ELISA), as previously described (9,  16). ELISA inhibition tests were performed by using 
increasing concentrations  of either  homologous or  heterologous  M  protein  as  soluble 
inhibitors of antibodies directed against a solid phase M antigen (15). 
Type-specific and cross-reactive opsonic antibodies were detected by in vitro opsono- 
phagocytic tests as described (10).  The test mixtures consisted of 0.05  ml of a standard 
suspension of streptococci, 0. l  ml of test serum, and 0.4  ml fresh human blood supple- 
mented  with  10  U/ml  heparin.  The  tubes  were  rotated  for  45  rain  at  37°C  and  the 
percentage of neutrophils  with  associated  streptococci  (percent phagocytosis) was esti- 
mated by microscopic counts of stained smears (10). 
Affinity Purification of M Protein Antibodies.  Type-specific and cross-reactive M protein 
antibodies were purified by affinity chromatography with columns of pep M5, pep M6, 
or pep M19,  covalently linked to Sepharose 4B (Pharmacia, Inc.,  Uppsala, Sweden),  as 
previously described (9).  One ml of pep M5 immune rabbit serum was loaded onto the 
column and incubated at ambient temperature for 30 rain. Serum proteins were eluted 
with phosphate-buffered saline (PBS)  until ultraviolet absorption at 230 nm reached the 
baseline level. M protein-specific antibodies were eluted with 0.2 M glycine/0.2 M NaCI, 
pH 2.8 (glycine-HC1),  immediately dialyzed against 0.02 M phosphate/0.15 M NaC1, pH 
7.4  (PBS),  and  then  concentrated  to  the  original  volume by membrane ultrafiltration 
(YM30 membrane; Amicon Corp., Scientific Systems Div., Lexington, MA). 
Specific heart-reactive antibodies were affinity purified from pep M5 rabbit antisera by 
using sarcolemmal membrane preparations (8,  9).  500-#g sarcolemmal membranes were 
washed by centrifugation with 3 ml PBS, followed by 3 ml glycine-HCl, and finally with 
PBS.  3 ml of immune rabbit serum were added to the washed membranes; the mixture 
was rotated end-over-end at 37 °C for 45 min and then centrifuged at 500 g for 15 min. 
The absorbed serum was retained and the membranes were washed three times with 3 
ml PBS.  Specific heart-reactive antibodies were eluted by incubating the membranes in 3 
ml glycine-HCI with constant mixing for  10 min. After centrifugation, the supernatant 
was sterilized  by membrane filtration (0.45  pore size;  Millipore Corp.,  Bedford,  MA), 
immediately dialyzed against  PBS,  and  concentrated  by membrane ultrafiltration  (see 
above) to a volume of 1 ml, 
Immunofluorescence  Tests.  Immune rabbit sera and  affinity-purified antibodies  were 
tested for the presence of heart-cross-reactive antibodies by indirect immunofluorescence 
tests using purified sarcolemmal membrane sheaths or frozen sections (4 #m) of human 
heart, as previously described (9). Immunofluorescence inhibition assays were performed 
by preincubating  immune  sera  (diluted  1:4  with  PBS)  or  affinity-purified  M  protein 
antibodies with either pep M5, pep M6,  pep M19, pep M24, or pep M6 plus pep M19 
(500 #g/ml) for 15 min at ambient temperature. A  drop of the mixture was applied to 
frozen sections of heart tissue or sarcolemmal membranes fixed to glass microscope slides, 
incubated for 30 rain at ambient temperature, and then washed three times in PBS. The 
slides were similarly treated with a 1:40 dilution of fluorescein-conjugated goat anti-rabbit 
lgG (Cappel Laboratories, Cochranville,  PA) and then  mounted with  1%  Gelvatol, pH 
i Abbreviations used in this paper:  BSA,  bovine serum albumin; ELISA, enzyme-linked immuno- 
sorbent assay; pep M, purified pepsin extracts of types 5, 6, 19, and 24 streptococci; PBS, phosphate- 
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7.0  (Monsanto,  Springfield,  MA)  and a  coverslip.  The  tissue  was  examined under  a 
fluorescence microscope (E. Leitz, Inc., Rockleigh, N  J). 
SDS-PAGE  and  Transblot  Analyses.  SDS-PAGE  of sarcolemmal membrane proteins 
was performed as previously described (9,  10) on continuous gradient gels ranging from 
10 to 20%. Electrophoresed proteins were transferred to nitrocellulose paper (9) which 
was cut into strips and incubated with affinity-purified M protein antibodies diluted 1:100 
in 0.05 M Tris]0.15 M NaCI, pH 7.4 with 1% bovine serum albumin (Tris-BSA). Inhibition 
experiments  were  performed  by adding  pep  M  protein  (20  ug/ml)  to  the  antibody 
preparation before adding the nitrocellulose strips.  After incubating at 37°C for 2 h, the 
strips were washed extensively with 0.05 M Tris/0.15  M NaCI, pH 7.4, then incubated 
with peroxidase-conjugated goat anti-rabbit IgG (Cappel  Laboratories), diluted 1:2000  in 
Tris-BSA, for 2 h at 37°C, and again washed extensively. The nitrocellulose paper was 
incubated with horseradish peroxidase substrate (Bio-Rad Laboratories, Richmond, CA) 
according to the manufacturer's instructions. 
Results 
Our previous studies (9) showed that of nine rabbits immunized with  100 ~g 
pep  M5,  only  one  developed  heart-cross-reactive  antibodies.  To  determine 
whether the immunity to tissue-cross-reactive epitopes could be obtained more 
consistently with a higher dose of M protein, we immunized three rabbits with a 
single  300  ~g dose  of pep  M5  emulsified in  complete  Freund's  adjuvant.  All 
three rabbits developed type-specific antibodies against the immunizing antigen, 
as  measured  by  ELISA  and by opsonophagocytic tests of homologous type  5 
streptococci  (Table  I).  When  tested  for  the  presence  of heart-cross-reactive 
antibodies,  all  three  immune  sera  were  strongly  positive,  as  determined  by 
indirect immunofiuorescence tests with purified sarcolemmai membrane sheaths 
(Table  I). To determine the pattern  of antibody deposition,  the antisera were 
reacted with frozen sections of fresh human myocardium (Fig.  1). The pattern 
of fluorescent antibody staining was sarcolemmal in distribution and  identical 
for each of the three antisera. 
Serotype  Distribution  of M  Protein  Heart-cross-reactive  Epitopes.  Because  pre- 
vious studies (9,  15) in our laboratories have shown that pep M5 shares epitopes 
with type 6  and type 19 M  proteins, we tested each of the heart-cross-reactive 
pep  M5  antisera  for  the presence  of cross-reactive  antibodies against purified 
TABLE  I 
Type-specific and Heart-reactive Antibodies Raised in Rabbits 
Immunized with Pep M5 
Percent 
Antiserum  ELISA titer  phagocytosis  Sarcolemmal  immuno-  against Pep M5  of type 5 
streptococci  fluorescence 
8329 preimmune  <200  2  0 
10 wk  25,600  88  ++++ 
8331 preimmune  <200  2  0 
10 wk  25,600  80  ++++ 
8332 preimmune  <200  6  0 
10 wk  12,800  80  ++++ 116  M  PROTEIN  HEART-CROSS-REACTIVE  EPITOPES 
FIGURE  1.  Immunofluorscence staining of human myocardium by pep M5 rabbit antiserum 
(8332).  (A) The immune serum bound to the sarcolemma in a somewhat patchy distribution, 
while the  preimmune  serum  (B) was  negative (the bright  staining areas were yellow rather 
than apple green, and are presumed to represent autofluorescence). 
TABLE II 
Type-specific and Cross-reactive Antibodies Raised in Rabbits 
Immunized with Pep M5 
Rabbit antiserum 
ELISA titer against: 
Pep M5  Pep M6  Pep M19  Pep M24 
8329  25,600  1,600  6,400  <200 
8331  25,600  3,200  6,400  <200 
8332  12,800  1,600  3,200  <200 
Preimmune pool  <200  <200  <200  <200 
pep M6, pep M 19, and pep M24 (Table II). All of the antisera showed significant 
cross-reactions with pep M6 and pep M19, but not with pep M24. A  sample of 
pooled preimmune sera was negative against all of the M proteins tested. 
Because all  of the  antisera  raised  against  pep  M5  were  cross-reactive  with 
human  heart  tissue and  also with  pep  M6 and  pep  M19,  it was of interest  to 
determine the serotype distribution of the heart-cross-reactive epitopes. One of 
the antisera  (8332) was chosen for further study in immunofluorescence inhibi- 
tion assays (Table III). M protein-specific antibodies were affinity purified with 
pep M5, pep M6, or pep M19 covalently linked to Sepharose 4B. The concen- 
tration of the purified antibodies was adjusted to result in a  3+ immunofluores- 
cence reaction with sarcolemmal membranes. Purified pep M proteins were used 
as soluble inhibitors of type-specific or cross-reactive, affinity-purified antibodies 
in immunofluorescence inhibition assays. 
All of the affinity-purified antibodies reacted strongly with sarcolemmal mem- 
branes by indirect immunofluorescence (Table III), indicating that pep M6 and 
pep M 19 share at least one heart-cross-reactive determinant  with pep M5. The 
binding of pep M5-specific antibodies to heart tissue was totally inhibited by pep 
M5, but only partially inhibited by pep M6 and pep M19, even at concentrations 
of 500 ttg/ml. When equal amounts of pep M6 and pep M19 were used together 
as soluble inhibitors  at a  total concentration  of 500 ttg/mi,  the pep  M5  heart- 
reactive antibodies were totally inhibited.  These results suggested that pep M5 DALE  AND  BEACHEY 
TABLE  III 
Type Specificity of Pep M5 Heart-reactive Antibodies Determined by 
Immunofluorescence Inhibition of Affinity-purified  Antiserum 
Antigen used for 
affinity purification 
Pep M5 
Sarcolemmal  Antigen used as inhibitor  immunofluorescence 
None  +++ 
Pep M5  0 
Pep M6  + 
Pep MI9  + 
Pep M6 +  Pep M19  0 
Pep M24  +++ 
Pep M6  None  +++ 
Pep M5  0 
Pep M6  0 
Pep M19  + 
Pep M24  +++ 
Pep M19  None  +++ 
Pep M5  0 
Pep M6  + 
Pep MI9  0 
Pep M24  +++ 
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FIGURE 2.  Schematic representative  of M  protein  heart-cross-reactive epitopes  based  on 
data obtained from the immunofluorescence inhibition assays (see Table lII). 
contains more than one heart-cross-reactive epitope and that they are shared in 
some combination by pep M6 and pep M 19. 
To futher define the location of the heart-cross-reactive epitopes on pep M6 
and pep M 19, the pep M5 antibodies were affinity purified on columns of pep 
M5,  pep  Mb,  or  pep  M19.  Sarcolemmal  immunofluorescence produced  by 
antibodies affinity purified with pep  M6 was totally inhibited by pep  M5,  the 
immunogen, and pep Mb, the antigen used for purification, but only partially 
inhibited by pep M 19 (Table I I I). Immunofluorescence by the pep M 19-purified 
antibodies  was  likewise  partially,  but  not  totally,  inhibited  by  pep  Mb.  The 
minimum number of pep  M5  heart-cross-reactive epitopes indicated by these 
results is three (Fig. 2). One of these epitopes is shared by pep M6 and pep M19, 
resulting in partial inhibition of the pep M5-purified, heart-reactive antibodies. 
Pep  M6  and pep  M19  each contain one of the other cross-reactive antigenic 118  M  PROTEIN  HEART-CROSS-REACTIVE  EP1TOPES 
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FIGURE  3.  Type specificity of pep M5 heart-cross-reactive epitopes determined by ELISA 
inhibition. Specific heart-reactive antibodies were eluted from sarcolemmal membranes and 
inhibition of binding to pep M5 was measured with increasing concentrations of pep M5 (O), 
pep M6 (+), pep M19 (A), pep M24 (A), or a combination of pep M6 and pep M19 (0). The 
highest concentration of soluble inhibitor was 40 ~g/ml. 
determinants, resulting in  complete inhibition of pep M5 antibodies when the 
heterologous M proteins are used in combination. 
To confirm the proposed distribution of heart-cross-reactive epitopes among 
the  M  proteins,  ELISA  inhibition  assays  were  performed  by  using  affinity- 
purified,  heart-reactive antibodies  eluted  from  sarcolemmal membranes.  Pep 
M5, pep M6, and pep M 19 were used as soluble inhibitors of antibodies directed 
against immobilized pep M5 (Fig. 3). Increasing concentrations of pep M5 totally 
inhibited the binding of purified, heart-reactive antibodies to immobilized pep 
M5.  Identical concentrations (10  #g/tube) of pep  M6  or pep M19  resulted in 
only ~50% inhibition, while pep M6 and pep M19, combined at a total concen- 
tration of 10 #g/tube, resulted in 100% inhibition (Fig.  3). These results confirm 
the presence of heart-cross-reactive epitopes on pep M6 and pep M 19 that are 
shared with pep M5, but only partially shared with each other (Fig. 2). 
Opsonization of  Homologous and Heterologous Streptococci by Pep M5 Heart-reactive 
Antibodies.  To determine whether the heart-cross-reactive epitopes of types 5, 
6, and 19 M proteins were protective determinants, the heart-reactive antibodies 
were affinity purified by absorption and elution from sarcolemmal membranes 
and then used in opsonization tests (Table IV). The immune serum opsonized 
types 5, 6, and  19,  but not type 24, streptococci. Absorption with sarcolemmal 
membranes partially reduced opsonization of types 5 and 6 organisms and totally 
abolished opsonization  of type  19  streptococci (Table  IV).  The  heart tissue- 
specific antibodies opsonized all three serotypes of streptococci, indicating that 
at least one of the heart-cross-reactive epitopes on each M protein was exposed 
on the surface of the organism and was available for antibody binding. 
Type Specificity of the  Sarcolemmal Membrane  Antigens  that  Cross-react With 
Streptococcal M Proteins.  Immunoblot analyses were used to identify the sarco- 
lemmal membrane proteins that cross-react with types 5,  6, and  19  M proteins DALE  AND  BEACHEY  1 19 
TABLE  IV 
Opsonization of Types 5, 6, and 19 Streptococci by Heart-reactive Antibodies Eluted from 
Human Heart Tissue 
Antiserum 
Percent of polymorphonuclear cells with 
associated streptococci: 
Type 5  Type 6  Type 19  Type 24 
8332 (10 wk)  80  76  57  0 
8332 absorbed with sarcolemmal membranes  66  14  4  0 
8332 eluted from sarcolemmal membranes  86  84  96  0 
8332 preimmune  6  0  0  0 
FIGURE 4.  Serotype specificity of M protein-cross-reactive sarcolemmal membrane proteins 
determined by immunoblot inhibition assays.  Sarcolemmal membrane proteins were electro- 
phoresed  in an SDS-polyacrylamide gel (A) and  then  transferred  to  nitrocellulose paper for 
immunoblot analyses (B-E).  Pep  M5-specific antibodies reacted with  multiple proteins (B). 
Pep M6 inhibited antibody binding to lower and higher molecular weight proteins (C) and pep 
M 19 inhibited antibody binding to lower molecular weight proteins only (D). Pep M5 totally 
inhibited antibody binding to the electropboresed proteins (E). 
(Fig.  4).  Multiple sarcolemmal  membrane proteins were discerned after staining 
SDS-polyacryamide  gels  that  were  electrophoresed  under  reducing  conditions 
(Fig.  4 A). The membrane proteins were transferred to nitrocellulose  paper and 
reacted  with antibodies  that  were affinity purified over a pep  M5  column.  The 
serotype specificity of the membrane antigens was determined by using pep M5, 
M6,  and  M19  as  soluble  inhibitors  of antibody  binding.  The  pep  M5-specific 
antibodies  reacted  with  multiple  membrane  proteins,  ranging  from  40,000  to 
200,000  mol wt (Fig. 4 B). Pep M6 inhibited antibody binding to several proteins 
of higher and lower molecular weight (Fig. 4 C), and pep M 19 inhibited antibody 
binding to lower molecular weight proteins (Fig.  4  D).  Pep M5  totally inhibited 
antibody to the sarcolemmal  membrane proteins (Fig. 4 E), indicating that all of 120  M  PROTEIN  HEART-CROSS-REACTIVE  EPITOPES 
the antibodies used in the assay were specific for pep M5. The preimmune rabbit 
serum was not reactive with any of the sarcolemmal membrane proteins (data 
not shown). 
Discussion 
In  the  present  study,  we  have  shown  that  three  serologically different  M 
proteins from potentially rheumatogenic group A streptococci contain epitopes 
within their covalent structures that are cross-reactive with sarcolemmal mem- 
brane proteins of human myocardium. By using affinity-purified antibodies in 
immunofluorescence and ELISA inhibition  tests,  we are able to  schematically 
map the locations of the heart-cross-reactive antigens on pep M5, pep M6, and 
pep M 19. Although the minimum number of cross-reactive epitopes within the 
pep  M5  molecule that  satisfy  our  results  is  three,  the  possibility  that  more 
epitopes  are  present  cannot  be  excluded by  our  data.  The  affinity-purified, 
heart-cross-reactive antibodies opsonized types 5,  6, and  19 streptococci, indi- 
cating that at  least one of the tissue-cross-reactive epitopes on each native M 
protein is a protective antigenic determinant. 
Previous studies  have shown that  tissue-cross-reactive antigens of group  A 
streptococci are  located  in  various  subcellular  components  of the  organism, 
including the cell wall (2,  5,  6) and protoplast  membrane (3,  8).  This  was of 
concern  to  early  investigators  attempting  to  develop  streptococcal  vaccines, 
because  of the  fear  that  partially  purified  M  protein  preparations  might  be 
contaminated with these cross-reactive antigens. Only recently (9) did we provide 
evidence that type 5 M protein contains at least one epitope that is shared with 
human heart tissue. By immunizing with a higher dose of pep MS, we have now 
shown the presence of multiple cross-reactive epitopes shared among types 5, 6, 
and  19,  but  not  24,  M  proteins.  Therefore,  we  can  no  longer  assume "that 
homogeneous M protein preparations will be free of potentially harmful tissue- 
cross-reactive epitopes. 
These findings emphasize the need to identify precisely the regions of the M 
proteins responsible for host tissue cross-reactivity so that they may be excluded 
from vaccine preparations.  Considerable progress has  recently been  made in 
determining the primary structures of several M protein molecules (10-14,  16- 
20). In addition, we have shown (16, 21-23) that natural and chemically synthe- 
sized peptide fragments of M protein, linked to appropriate carrier molecules, 
evoke opsonic antibodies, indicating that immunity against the entire M protein 
is not necessary to protect against infection. Laboratory animals immunized with 
a chemically synthesized peptide of type 5 M protein, containing only 20 amino 
acid residues, developed opsonic antibodies that were not heart-cross-reactive 
(23).  Thus,  by selecting limited regions of the  M  protein  molecule to  use as 
protective immunogens, the total amount of each M protein represented in a 
vaccine preparation can be minimized and the risk of evoking potentially harmful 
tissue-cross-reactive antibodies can be reduced. The antisera described in the 
present study will provide useful tools to identify fragments of M proteins that 
contain host tissue-cross-reactive epitopes. The cross-reactive subpeptides, which 
may  be  structurally  defined  and  even  chemically  synthesized,  may  provide DALE  AND  BEACHEY  121 
valuable insights into the pathogenesis of streptococcal infection and possibly the 
pathogenesis of acute rheumatic fever and rheumatic carditis. 
Summary 
We present evidence that a highly purified pepsin extract of type 5 streptococ- 
cal M  protein (pep  M5) contains at least three epitopes that are cross-reactive 
with sarcolemmal membrane proteins of human myocardium. The tissue-cross- 
reactive determinants of pep M5 are also partially shared with pep M6 and pep 
M 19. Three rabbits immunized with a single 300 ~g dose of pep M5 developed 
significant levels of heart-cross-reactive antibodies, as  determined by indirect 
immunofluorscence tests.  All  three  sera  also contained antibodies that  cross- 
reacted with pep  M6  and pep  M19.  The heart tissue-specific antibodies that 
were eluted from sarcolemmal membranes opsonized types 5, 6, and 19  strep- 
tococci, indicating that they were directed against protective M protein epitopes 
on the surface of virulent organisms. Immunofluorescence inhibition tests, using 
purified  M  proteins  as  soluble  inhibitors  of  heart-cross-reactive  antibodies, 
revealed the number and  M  protein serotype distribution of the tissue-cross- 
reactive  epitopes.  Immunobiot analyses demonstrated the  sarcolemmal  mem- 
brane proteins containing the various cross-reactive antigenic determinants. 
We wish to acknowledge the contributions  of  James Kuykendal, who participated in some 
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